Market Research Logo

Global Actinic Keratosis Drugs Market 2017-2021

Global Actinic Keratosis Drugs Market 2017-2021

About Actinic Keratosis Drugs

Actinic keratosis is a pre-stage non-melanoma skin cancer caused by exposure to ultraviolet (UV) rays. Initially, the skin has a sandpaper-like texture with lesions. It can develop into squamous cell carcinoma, if not treated. The actinic keratosis drugs market includes nucleoside metabolic inhibitors, photosensitizers, nonsteroidal anti-inflammatory drugs (NSAIDs), and immunomodulators.

Technavio’s analysts forecast the global actinic keratosis drugs market to grow at a CAGR of 3.32% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global actinic keratosis drugs market for 2017-2021. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Actinic Keratosis Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Almirall
  • GALDERMA
  • LEO Pharma
  • Valeant
Other prominent vendors
  • Biofrontera
  • Novartis
  • Perrigo
  • Promius Pharma
  • Taro Pharmaceutical Industries
  • TOLMAR Pharmaceuticals
  • Vidac Pharma
Market driver
  • High prevalence of actinic keratosis
  • For a full, detailed list, view our report
Market challenge
  • Alternative treatment options
  • For a full, detailed list, view our report
Market trend
  • Novel drug delivery mechanisms
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?


Press Release

Technavio Announces the Publication of its Research Report – Global Actinic Keratosis Drugs Market 2017-2021

Technavio recognizes the following companies as the key players in the global actinic keratosis drugs market: Almirall, GALDERMA, LEO Pharma, and Valeant.

Other Prominent Vendors in the market are: Biofrontera, Novartis, Perrigo, Promius Pharma, Taro Pharmaceutical Industries, TOLMAR Pharmaceuticals, and Vidac Pharma.

Commenting on the report, an analyst from Technavio’s team said: “One trend in the market is novel drug delivery mechanisms. The advent of novel drug delivery systems such as microneedles will improve the efficacy and bioavailability of the already marketed formulations. Microneedling has evolved as an adjuvant therapy to the drug treatment available for actinic keratosis.”

According to the report, one driver in the market is high prevalence of actinic keratosis. Actinic keratosis develops mainly due to UV exposure. The lesions arising from actinic keratosis can lead to squamous cell carcinoma if left untreated. With the growing awareness of oncology, people believe in choosing causative treatment. This leads to a higher incidence rate of actinic keratosis treatment, which has been driving the market growth. The prevalence is high in individuals with fair skin and in regions with high exposure to the sun such as those near the equator. As per the NIH, the prevalence rate of actinic keratosis was estimated to be 40%-50% in the Caucasian population aged above 40 years.

Further, the report states that one challenge in the market is alternative treatment options. The availability of better alternative treatment modalities is the biggest challenge for the global actinic keratosis drugs market. The treatment of actinic keratosis through techniques such as cryotherapy and chemical peeling is more popular than treatment through drugs due to their better efficacy. Cryotherapy freezes the cells affected by actinic keratosis by applying liquid nitrogen to the area and thereby stops the disease growth. Considering that such quick therapies save on time and are convenient for patients, their popularity is only expected to grow over time.

Companies Mentioned

Almirall, GALDERMA, LEO Pharma, Valeant, Biofrontera, Novartis, Perrigo, Promius Pharma, Taro Pharmaceutical Industries, TOLMAR Pharmaceuticals, and Vidac Pharma.

  • Executive summary
  • Scope of the report
  • Research methodology
  • Introduction
    • Market outline
  • Disease overview
    • Actinic keratosis
  • Market landscape
    • Market overview
      • Table Global actinic keratosis drugs market
    • Market size and forecast
      • Table Global actinic keratosis drugs market 2016-2021 ($ millions)
    • Five forces analysis
      • Table Five forces analysis
  • Pipeline
    • Table Pipeline landscape by development phase
    • Table Key clinical trials
  • Market segmentation by drug class
    • Table Global actinic keratosis drugs market by drug class 2016
    • Table Global actinic keratosis drugs market by drug class 2021
    • Nucleoside metabolic inhibitors
      • Table Global actinic keratosis drugs market by nucleoside metabolic inhibitors 2016-2021 ($ millions)
    • Immunomodulators
      • Table Global actinic keratosis drugs market by immunomodulators 2016-2021 ($ millions)
    • Photosensitizers
      • Table Global actinic keratosis drugs market by photosensitizers 2016-2021 ($ millions)
    • NSAIDs
      • Table Global actinic keratosis drugs market by NSAIDs 2016-2021 ($ millions)
  • Regional landscape
    • Table Global actinic keratosis drugs market by geography 2016-2021 (% share)
    • Regional comparison
      • Table Regional comparison
    • Actinic keratosis drugs market in Americas
      • Table Actinic keratosis drugs market in Americas 2016-2021 ($ millions)
      • Table Actinic keratosis drugs market in Americas - Year over year growth 2017-2021
    • Actinic keratosis drugs market in EMEA
      • Table Actinic keratosis drugs market in EMEA 2016-2021 ($ millions)
      • Table Actinic keratosis drugs market in EMEA - Year over year growth 2017-2021
    • Actinic keratosis drugs market in APAC
      • Table Actinic keratosis drugs market in APAC 2016-2021 ($ millions)
      • Table Actinic keratosis drugs market in APAC - Year over year growth 2017-2021
    • Key leading countries
      • Table Key leading countries
    • Market opportunity
  • Decision framework
  • Drivers and challenges
    • Market drivers
    • Market challenges
  • Market trends
    • Novel drug delivery mechanisms
    • Advanced diagnostic techniques
    • Drug development by 3D tissue modelling
    • Industry focus on actinic keratosis R&D activity
    • Development of targeted drugs having selectivity to cells
  • Vendor landscape
    • Almirall
      • Table Almirall: Key highlights
      • Table Almirall: Strength assessment
      • Table Almirall: Strategy assessment
      • Table Almirall: Opportunity assessment
    • GALDERMA
      • Table GALDERMA: Key highlights
      • Table GALDERMA: Strength assessment
      • Table GALDERMA: Strategy assessment
      • Table GALDERMA: Opportunity assessment
    • LEO Pharma
      • Table LEO Pharma: Key highlights
      • Table LEO Pharma: Strength assessment
      • Table LEO Pharma: Strategy assessment
      • Table LEO Pharma: Opportunity assessment
    • Valeant
      • Table Valeant: Key highlights
      • Table Valeant: Strength assessment
      • Table Valeant: Strategy assessment
      • Table Valeant: Opportunity assessment
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report